Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

FT819

Phase 2Small molecule

FFate Therapeutics

FT819 is one of 91 small molecule programs targeting Lupus Nephritis. It is currently in Phase 2.

3

Indications

3

Total Trials

3

Active Trials

90

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lupus NephritisRecruiting

B-Cell MalignanciesActive, not recruiting

Autoimmune DiseaseRecruiting

Lupus NephritisPhase 2

Recruiting

B-Cell MalignanciesPhase 1

Active, not recruiting

Autoimmune DiseasePhase 1

Recruiting

Competition

Competitive Landscape

74 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Atgam

Cytosar

Rayos

RRoxane Laboratories

Bicnu

MMelissa K Accordino

Alkeran

Vepesid

Fludara

Cytoxan

BBaxter Healthcare Corporation

CAR-T Cell

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Anti-CD19 CAR-T Cells

TThe Children's Hospital of Zhejiang University School of Medicine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2Recruiting

Lupus Nephritis

NCT07570862

Q3 2039

Phase 1Active, not recruiting

B-Cell Malignancies

NCT04629729

Q3 2042

Phase 1Recruiting

Autoimmune Disease

NCT06308978

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Recruiting·FFate Therapeutics·Phase 1·NCT06308978·244 enrolled

B-cell Malignancies1 trial

FT819 in Subjects With B-cell Malignancies

Active, not recruiting·FFate Therapeutics·Phase 1·NCT04629729·54 enrolled

Lupus Nephritis1 trial

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe Systemic Lupus Erythematosus With Lupus Nephritis (RECLAIM-LN)

Recruiting·FFate Therapeutics·Phase 2·NCT07570862·53 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for FT819. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FT819 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FT819. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fate Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFate Therapeutics

Related News